Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium

Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium

Related Keywords

,Privacy Policy ,Ark Biopharmaceutical ,Hase 3 Airflo Study ,Iresovir ,Sv Infected ,Infants ,2th International Rsv Symposium ,Ealth Press Release ,